2022 total revenue expected to meet or exceed top end of guided range of $132–137 million
Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021
Growth of 37% year over year in DecisionDx®-Melanoma test report volume
Year-end 2022 cash, cash equivalents and marketable investment securities expected to be approximately $259 million
https://finance.yahoo.com/news/castle-biosciences-announces-preliminary-fourth-000000241.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.